
GlaxoSmithKline (GSK) with its partner, the National Institute of Allergy and Infectious Diseases (NIAID), is expected to begin a phase 1 trial this fall on a potential vaccine for the treatment of Ebola virus, a deadly disease that has killed approximately 1,000 in a recent outbreak in West Africa, according to a report by Reuters.
